Compare Divis Laboratories with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC PHARMA DIVIS LABORATORIES/
ALEMBIC PHARMA
 
P/E (TTM) x 35.9 15.6 230.5% View Chart
P/BV x 6.7 3.9 172.4% View Chart
Dividend Yield % 0.9 1.0 93.0%  

Financials

 DIVIS LABORATORIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ALEMBIC PHARMA
Mar-19
DIVIS LABORATORIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639664 246.9%   
Low Rs1,115412 270.4%   
Sales per share (Unadj.) Rs186.3208.7 89.3%  
Earnings per share (Unadj.) Rs51.031.0 164.4%  
Cash flow per share (Unadj.) Rs57.337.1 154.5%  
Dividends per share (Unadj.) Rs16.005.50 290.9%  
Dividend yield (eoy) %1.21.0 113.7%  
Book value per share (Unadj.) Rs261.8144.2 181.5%  
Shares outstanding (eoy) m265.47188.52 140.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.6 286.6%   
Avg P/E ratio x27.017.4 155.7%  
P/CF ratio (eoy) x24.014.5 165.7%  
Price / Book Value ratio x5.33.7 141.0%  
Dividend payout %31.417.7 177.0%   
Avg Mkt Cap Rs m365,592101,461 360.3%   
No. of employees `00011.8NA-   
Total wages/salary Rs m5,4237,467 72.6%   
Avg. sales/employee Rs Th4,175.1NM-  
Avg. wages/employee Rs Th457.7NM-  
Avg. net profit/employee Rs Th1,141.8NM-  
INCOME DATA
Net Sales Rs m49,46339,347 125.7%  
Other income Rs m1,55694 1,659.2%   
Total revenues Rs m51,01939,441 129.4%   
Gross profit Rs m18,7188,736 214.3%  
Depreciation Rs m1,6891,152 146.6%   
Interest Rs m35184 19.0%   
Profit before tax Rs m18,5517,493 247.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,568 320.5%   
Profit after tax Rs m13,5275,844 231.5%  
Gross profit margin %37.822.2 170.5%  
Effective tax rate %27.120.9 129.4%   
Net profit margin %27.314.9 184.1%  
BALANCE SHEET DATA
Current assets Rs m46,50119,577 237.5%   
Current liabilities Rs m8,46814,896 56.8%   
Net working cap to sales %76.911.9 646.3%  
Current ratio x5.51.3 417.9%  
Inventory Days Days13190 145.8%  
Debtors Days Days8645 189.3%  
Net fixed assets Rs m25,79727,097 95.2%   
Share capital Rs m531377 140.8%   
"Free" reserves Rs m68,96226,811 257.2%   
Net worth Rs m69,49327,188 255.6%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m80,38347,778 168.2%  
Interest coverage x531.041.7 1,273.4%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.60.8 74.7%   
Return on assets %16.912.6 133.7%  
Return on equity %19.521.5 90.6%  
Return on capital %26.723.6 113.3%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23819,453 212.0%   
Fx outflow Rs m12,4056,065 204.5%   
Net fx Rs m28,83313,388 215.4%   
CASH FLOW
From Operations Rs m9,5438,120 117.5%  
From Investments Rs m-6,854-7,556 90.7%  
From Financial Activity Rs m-2,459590 -416.6%  
Net Cashflow Rs m2301,153 19.9%  

Share Holding

Indian Promoters % 52.0 74.1 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 2.9 406.9%  
FIIs % 19.0 9.1 208.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 13.9 123.7%  
Shareholders   31,796 49,328 64.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 15, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ORCHID PHARMA LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS